Mukund Kumar
Rheumatology · Norfolk, NENPI 1659896694
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 42 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Amgen at 26.7% of the total. That places this record below the midpoint for rheumatology clinicians in NE, where the typical reported total is $784.
Across 42 payments — averaging $18.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$210
- AbbVie$139
- Johnson & Johnson$91
- AstraZeneca$70
- Abbott$44
- Sanofi$38
- plus $194 from 8 others
What the payments were for
- Food & beverage$784100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 12 | $210 |
| AbbVie | 7 | $139 |
| Johnson & Johnson | 5 | $91 |
| AstraZeneca | 4 | $70 |
| Abbott | 2 | $44 |
| Sanofi | 1 | $38 |
| Mallinckrodt Hospital Products Inc. | 2 | $35 |
| Kyowa Kirin, Inc. | 2 | $31 |
| Novartis | 2 | $31 |
| Aurinia Pharma U.S., Inc. | 1 | $24 |
| Organon | 1 | $20 |
| UCB, Inc. | 1 | $19 |
| Pfizer | 1 | $19 |
| Genentech USA, Inc. | 1 | $16 |
How this compares
$784 in reported general payments places this provider in the 50th percentile of 39 rheumatology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydroxychloroquine Sulfate | 246 | $8,629 |
| MethotrexateMethotrexate Sodium | 196 | $6,485 |
| Duloxetine Hcl | 76 | $2,360 |
| Leflunomide | 48 | $2,106 |
| Prednisone | 330 | $1,646 |
| Mycophenolate Mofetil | 23 | $1,584 |
| Sulfasalazine | 22 | $733 |
| Colchicine | 17 | $732 |
| Celecoxib | 33 | $730 |
| Allopurinol | 74 | $508 |
| Cyclobenzaprine Hcl | 57 | $384 |
| Meloxicam | 100 | $298 |
| Methylprednisolone | 16 | $259 |
| Methotrexate SodiumMethotrexate Sodium/Pf | 19 | $226 |
| Folic Acid | 28 | $221 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Norfolk
- Abhijeet DanveOmaha$118K
- Jay KenikOmaha$69K
- Lynell KlassenOmaha$68K
- William PalmerOmaha$24K
- Ted MikulsOmaha$23K
- Melvin ChurchillLincoln$14K
- Amandeep RakhraOmaha$12K
- Diana MeylerLincoln$12K
- Kristin LakeNorth Platte$7K
- Carolyn CoyleOmaha$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.